FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

A new report from congressional researchers examines the state of law around a federal statute that prohibits gun possession ...

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Citizen’s Petition Filed Requesting FDA Approve NurOwn™ On July 3, 2025, a Citizen’s Petition was filed with the U.S. Food and Drug ...

Milestone Pharmaceuticals Inc. is a strong buy under $2 with FDA approval for Cardamyst expected in 2026, offering unique ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Joseph Jacob, MD, discusses the promising impact of TAR-200.

Shares of Instil Bio jumped after federal regulators cleared the investigational new drug application for its tumor treatment AXN-2510. The stock was up 11% at $24.38 in early trading. Shares were ...

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...